MET Fusions in NSCLC: Clinicopathologic Features and Response to MET Inhibition

This publication has 14 references indexed in Scilit:

• MET-dependent solid tumours — molecular diagnosis and targeted therapy
  Nature Reviews Clinical Oncology, 2020
• MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
  Clinical Cancer Research, 2020
• Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
  Annals of Oncology, 2019
• Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib
  Journal of Thoracic Oncology, 2019
• Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
  Clinical Cancer Research, 2018
• Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
  Nature Medicine, 2017
• Recurrent MET fusion genes represent a drug target in pediatric glioblastoma
  Nature Medicine, 2016
• Activating MET kinase rearrangements in melanoma and Spitz tumours
  Nature Communications, 2015
• The landscape of kinase fusions in cancer
  Nature Communications, 2014
• ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer
  Clinical Cancer Research, 2013